pISSN 2234-3806eISSN 2234-3814
Table. 2.
Factors associated with symptomatic breakthrough infection after a third vaccination dose
| Variables | Breakthrough infection (N=64) | No breakthrough infection (N=222) | Univariable | Multivariable |
|||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | ||||||
| Age, median (IQR), yrs | 50.0 (40.5–59.5) | 49.0 (38.0–60.0) | 1.00 | 0.99–1.02 | 0.644 | ||||
| Male sex, N (%) | 34 (53.1) | 114 (51.4) | 1.07 | 0.62–1.88 | 0.802 | ||||
| Time since transplantation, median (IQR), yrs | 4.0 (1.6–9.6) | 6.1 (2.2–11.3) | 0.96 | 0.91–1.00 | 0.075 |
||||
| Dialysis duration, median (IQR), month | 8.3 (0–48.3) | 14.6 (1.9–64.8) | 0.99 | 0.99–1.00 | 0.089 |
0.99 | 0.99–1.00 | 0.066 | |
| Donor type–living donor, N (%) | 48 (75.0) | 137 (61.7) | 1.86 | 1.01–3.57 | 0.052 |
||||
| Hypertension, N (%) | 42 (65.6) | 124 (55.9) | 1.51 | 0.85–2.73 | 0.164 |
||||
| Steroid dose, median (IQR) | 5.0 (2.5–5.0) | 5.0 (2.5–5.0) | 1.08 | 0.99–1.19 | 0.068 |
1.08 | 0.99–1.18 | 0.069 | |
| PLR | 121.6 (89.5–162.0) | 111.1 (86.4–146.8) | 1.00 | 1.00–1.01 | 0.070 |
||||
| Tacrolimus trough level, ng/mL | 6.0 (5.2–7.0) | 5.4 (4.5–6.6) | 0.91 | 0.35–2.40 | 0.171 |
||||
| Type of primary vaccination, N (%) | |||||||||
| mRNA/mRNA vaccine | 21 (41.2) | 30 (41.7) | Ref | ||||||
| ChAdOX1-S/ChAdOX1-S | 17 (33.3) | 23 (31.9) | 1.01 | 0.48–2.02 | 0.988 | ||||
| ChAdOX1-S/BNT162b2 | 13 (25.5) | 18 (25.0) | 0.85 | 0.43–1.63 | 0.631 | ||||
| Janssen | 0 | 1 (1.4) | 0.00 | 0.988 | |||||
| Type of third dose vaccine, N (%) | |||||||||
| mRNA-1273 | 6 (9.4) | 34 (15.3) | Ref | ||||||
| BNT162b2 | 58 (90.6) | 188 (84.7) | 1.75 | 0.75–4.81 | 0.232 | ||||
| Post-third dose anti-spike antibody titer <400 AU/mL, N (%) | 36 (56.2) | 61 (27.5) | 3.39 | 1.92–6.07 | <0.001 |
3.46 | 1.93–6.20 | <0.001 | |
*The multivariable logistic regression model included sex, age, and factors with
†Post-booster anti-RBD IgG titer was <400 AU/mL.
Abbreviations: IQR, interquartile range; PLR, platelet:lymphocyte ratio; Ref, reference; RBD, receptor-binding domain.
Ann Lab Med 2024;44:64~73 https://doi.org/10.3343/alm.2024.44.1.64
© Ann Lab Med